secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001104659-26-052107
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff
--------------------------------------------------------------------------

- Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.
- Cash $559.5M at March 31, 2026; expects runway into 2030 after cost cuts.
- Workforce reduced ~30%; annual operating expenses expected to drop ~50%.
- Duravelo-2 (zelenectide) converted to randomized Phase 2; Duravelo-3/4 trials discontinued.
- Phase 2 trial of nuzefatide in pancreatic cancer started; first patient dosed April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/0001104659-26-052107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/tm2613019d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-052107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer